This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

EPlerenone neuroHormonal Efficacy and SUrvival Study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The EPHESUS trial (1) recruited 6632 patients with heart failure or left ventricular dysfunction in the context of acute myocardial infarction. In addition to conventional treatment patients were randomised to the selective aldosterone antagonist eplerenone or placebo.

The study found a clear 15% reduction in all-cause mortality. Eplerenone (in addition to standard therapy) significantly reduced mortality in patients with LVSD and heart failure equating to a NNT of 44 for all-cause mortality and 50 for mortality associated with cardiovascular disease.

This trial shows that aldosterone antagonists are useful even in asymptomatic left ventricular dysfunction as well as more severe heart failure (2).

Eplerenone use is associated with the an increased risk of hyperkalaemia compared with placebo (3.4% vs 2%, p < 0.001). The incidence of gynaecomastia as an adverse effect is low and occurred with equal incidence in the eplerenone and placebo treated groups (3).

References:

  1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348(22):2271.
  2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341(10):709-17.
  3. Midland Therapeutic Review and Advisory Committee (March 2005). Eplerenone.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.